A single tumour DNA molecule among more than a million others. That is how small a trace of cancer Abbott’s upgraded ...

US biotech company Artiva Biotherapeutics is discontinuing the development of a cell therapy for autoimmune diseases and laying off 94 per cent of its workforce after two patients died during a ...

Medical breakthroughs have transformed healthcare, but scientific progress alone is not enough. As misinformation spreads and trust in science comes under pressure, how can we ensure that healthcare ...

Danish biotech company ResoTher Pharma, which is developing drugs to treat heart conditions, plans to list on the Swedish ...

AstraZeneca is considering developing cancer vaccines based on mRNA technology, CEO Pascal Soriot said at a conference on Tuesday, Bloomberg News reports.

Two multibillion-dollar deals, the company’s first profit and an oversubscribed share issue. After an eventful year, AlzeCure ...

After a long and winding road, Xbrane has now received FDA approval for Lucamzi, a biosimilar to the eye drug Lucentis.

A new drug combination extended survival by more than eight months in patients with extensive-stage small cell lung cancer, ...

AstraZeneca’s Enhertu is moving into earlier-stage breast cancer treatment after winning EU approval. In a phase III trial, ...

Following a sharp decline in sales, Swedish medtech company Miris is planning a SEK 20 million rights issue. At the same time ...

A new prostate cancer pill achieved a tumour response in 75 per cent of patients whose tumours could be measured in a phase I ...

Roche’s investigational cancer drug divarasib reduced the risk of death by 44 per cent compared with existing treatments in a phase III trial involving patients with lung cancer.